UCL Business Ltd
🏢 View company profile →125Patents
125Active
125Granted
61Portfolio score
Filing activity: Jul 5, 2011 → Jan 22, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10730942B2 | Protein-based T-cell receptor knockdown | Chemistry; Metallurgy | 11 | Active |
| US10525029B2 | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies | Human Necessities | 7 | Active |
| US10829547B2 | Anti-tau antibodies and uses thereof | Chemistry; Metallurgy | 6 | Active |
| US10610506B2 | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | Human Necessities | 4 | Active |
| US11745010B2 | Nerve stimulation device for current steering | Human Necessities | 3 | Active |
| US11306142B2 | Bispecific antibodies to ROR1 and CD3 | Chemistry; Metallurgy | 3 | Active |
| US10792395B2 | Methods and devices for the production of decellularised tissue scaffolds | Chemistry; Metallurgy | 3 | Active |
| US11466083B2 | ROR1 antibodies | Chemistry; Metallurgy | 2 | Active |
| US10478457B2 | Chimeric protein | Emerging Cross-Sectional Technologies | 2 | Active |
| US10925943B2 | Marker-suicide gene useful in adoptive cell therapy | Chemistry; Metallurgy | 2 | Active |
| US11006881B2 | Detecting activity in peripheral nerves | Human Necessities | 2 | Active |
| US10548866B2 | Therapeutic use of compounds | Human Necessities | 2 | Active |
| US11789012B2 | Cell death biomarker | Physics | 1 | Active |
| US10745715B2 | Method and means for purifying retroviral vectors | Chemistry; Metallurgy | 1 | Active |
| US11967435B2 | Modeling of flow through a left ventricular assist device (LVAD) | Physics | 1 | Active |
| US11749694B1 | Photoconductive metasurface-based ultrafast device | Electricity | 1 | Active |
| US10842885B2 | Factor IX encoding nucleotides | Chemistry; Metallurgy | 1 | Active |
| US11869132B2 | Neural network based 3D object surface mapping | Physics | 1 | Active |
| US10792336B2 | Method of treating hemophilia A | Human Necessities | 1 | Active |
| US11643451B2 | T cell receptor | Human Necessities | 1 | Active |
| US11723925B2 | ROR1 CAR T-cells | Chemistry; Metallurgy | 1 | Active |
| US10611811B2 | Ligand | Physics | 1 | Active |
| US11517631B2 | Factor IX encoding nucleotides | Chemistry; Metallurgy | 1 | Active |
| US10752665B2 | April variants | Physics | 1 | Active |
| US11387479B2 | Flow batteries with current collectors having a dielectric coating | Emerging Cross-Sectional Technologies | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.